Biography
Dr. Yi Zhang received his MD from Henan Medical University and MS from Tongji Medical University. He obtained his PhD at Université Catholique de Louvain in Belgium and did his postdoctoral training in Drs Thierry Boon and Pierre van der Bruggen’s lab in Ludwig Institute for Cancer Research, Brussels Branch. After that, he moved to University of Chicago and worked as Research Assistant Professor in Dr. Hans Schreiber’s lab. In 2005, he was recruited as Tenure-track Assistant Professor in Medical University of South Carolina. Currently, he is a distinguished Professor and Director in Biotherapy Center & Cancer Center at the First Affiliated Hospital of Zhengzhou University. His laboratory investigates the key cellular components such as effector T cells, regulatory immune cells and caner stem cells in tumor microenvironment and their clinical relevance, especially in lung cancer and esophageal cancer. He concentrates on the aberrant expression of cancer-testis (CT) antigens (such as MAGE-A3, MAGE-C2, NY-ESO-1 etc.) and the corresponding antigen-specific T cells in lung cancer and esophageal cancer. Furthermore, they are dedicated to develop TCR or CAR gene-modified T cells and against tumor antigens for potential antigen-specific T cell therapy. He published 184 papers and 85 publications in internationally peer-reviewed journals.
Research Interest
He concentrates on the aberrant expression of cancer-testis (CT) antigens (such as MAGE-A3, MAGE-C2, NY-ESO-1 etc.) and the corresponding antigen-specific T cells in lung cancer and esophageal cancer.
Biography
Qiao Li, Ph.D., has long been involved in both animal studies and clinical trials in cancer immunotherapy. His laboratory research interests focus on the development of cancer immunotherapy using immune cells, such as T cells, B cells and dendritic cells (DCs). Specifically, application of anti-tumor B cells, and generation of DC-based cancer stem cell (CSC) vaccines to target cancer stem cells represent novel directions in cancer immunotherapy. Administration of DC-CSC vaccine targeting CSCs inhibited local tumor recurrence, reduced spontaneous lung metastasis, and prolonged animal survival. Mechanistically, his novel CSC vaccination strategy conferred host both antibody responses and CTL functions against cancer stem cells which resulted in significantly reduced number of cancer stem cells in the treated host.
Research Interest
His laboratory research interests focus on the development of cancer immunotherapy using immune cells, such as T cells, B cells and dendritic cells (DCs).
Biography
Dr. Salah Aref is currently working as professor of Hematology in Mansoura University; Egypt; and Director of Mansoura University Oncology Center Laboratories. He is also working as Member in National board for promotion of Professors in Hematology. He completed his education from The Mansoura University. He published more than 60 papers in the field of hemato-oncology. He received many awards from Egyptian National Academy of Science; Mansoura University and International Society of Laboratory Hematology. He is acting as Editorial Board Member and Peer Reviewer of many peer reviewed international journals and authored many books.
Research Interest
Dr.Salah Aref`s research interest are in Hematological Oncology field,Molecular Study of Hematological Disorders,Angiogenesis in Hematological Malignancies